title: A repertoire of biomarkers helps in detection and assessment of therapeutic response in epithelial ovarian cancer.
abstract: In epithelial ovarian cancer (EOC), the cancer antigen 125 (CA-125) has been conventionally used to help in diagnosis and assessment of response to treatment. Currently, YKL-40 (Tyrosine-Lysine-Leucine-40) and circulating cell-free DNA are being evaluated for possession of similar ability. In this study, we aimed to assess the ability of a repertoire of potential biomarkers in detecting and assessing therapeutic response, in advanced EOC. Blood levels of CA-125, YKL-40, total cell-free DNA (CFDNA), cell-free nuclear DNA (CFnDNA), and cell-free mitochondrial DNA (CFmDNA) levels were measured in 100 untreated patients of advanced EOC from November 2009 to June 2011, and again on treatment completion from the 20 patients who appeared for follow-up analysis. Significantly, higher proportion of untreated patients had serum CA-125 >3 times upper limit of normal (ULN) (90.0%; P < 0.0001) and plasma YKL-40 >ULN (77.0%; P < 0.0001), both of which significantly decreased, Posttherapy. posttherapy, CFDNA (P < 0.0001), and CFnDNA (P < 0.0001) levels significantly decreased as compared to pretreatment levels. Positive and significant correlations existed between pretherapy CFDNA and CFnDNA [Spearman rho (ρ) = 1.000; P < 0.0001], and also with CFmDNA (ρ = 0.301; P = 0.002), separately between CFnDNA and CFmDNA (ρ = 0.303; P = 0.002), as well as between plasma YKL-40 and patient age (ρ = 0.353; (P < 0.0001). On treatment completion, CFDNA and CFnDNA levels showed positive and significant correlation (ρ = 1.000; P < 0.0001). Therefore serum CA-125 and plasma YKL-40 aid detection and assessment of therapeutic response, in advanced EOC. CFDNA and CFnDNA help in estimating extent of therapeutic response in advanced EOC.
authors.affiliation: Department of Biochemistry, All India Institute of Medical Sciences, Room No. 3027A, New Delhi, 110029, India.
authors.forename: Sharmistha
authors.initials: S
authors.lastname: Choudhuri
authors.forename: Chandresh
authors.initials: C
authors.lastname: Sharma
authors.forename: Ayan
authors.initials: A
authors.lastname: Banerjee
authors.forename: Sunesh
authors.initials: S
authors.lastname: Kumar
authors.forename: Lalit
authors.initials: L
authors.lastname: Kumar
authors.forename: Neeta
authors.initials: N
authors.lastname: Singh
mesh_terms: D054392:Adipokines / Q000097:blood; D001483:Base Sequence; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018394:CA-125 Antigen / Q000097:blood; D000077216:Carcinoma, Ovarian Epithelial; D000071451:Chitinase-3-Like Protein 1; D017931:DNA Primers; D004272:DNA, Mitochondrial / Q000378:metabolism; D005260:Female; D006801:Humans; D037102:Lectins / Q000097:blood; D009375:Neoplasms, Glandular and Epithelial / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy*; D060888:Real-Time Polymerase Chain Reaction
chemical_list: D054392:Adipokines; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1; D017931:DNA Primers; D004272:DNA, Mitochondrial; D037102:Lectins